New indications approved, new options for targeted therapy of lupus nephritis

2022-09-02 0 By

Glaxosmithkline (GSK) today announced the launch of Belizumab for lupus nephritis in China.Belliumab is the first drug approved for the treatment of systemic lupus erythematosus and adult lupus nephritis in the world and China. The launch of the new indication in China will break the existing dilemma in the treatment of lupus nephritis and provide patients with a new option for targeted treatment of biological agents.According to statistics, about 40%-60% of patients with systemic lupus erythematosus (SLE) have lupus nephritis at the beginning of the disease, and the recurrence rate is as high as 33%-40%.10-20% of patients with lupus nephritis will progress to end-stage renal disease within 5 years of diagnosis, and lupus nephritis is an important cause of death in SLE patients.In order to understand the therapeutic effect of targeted drugs, blISS-LN, the largest and longest phase 3 clinical trial of active lupus nephritis, was conducted worldwide. Professor Yu Xueqing, President of Guangdong Provincial People’s Hospital in China, as the principal investigator, said:”Previous treatment regimens for lupus nephritis based on hormone combined immunosuppressants still have problems such as low renal remission rate, high recurrence rate, and obvious toxic and side effects of long-term treatment drugs.”The combination of the biologically-targeted agent beliuzumab with conventional therapy significantly improves renal response in patients with lupus nephritis, significantly reduces the risk of nephro-related events/death in patients with lupus nephritis, reduces recurrence, infection, and hormone use, and is generally safe and well tolerated, ultimately contributing to long-term treatment goals for lupus nephritis.”Due to the unsatisfactory control of the disease, a considerable number of patients face the risk of recurrence, and each recurrence will cause more serious damage to kidney function, and even many patients will progress to kidney failure, requiring kidney dialysis or kidney transplantation.Professor Yu emphasized that the treatment of lupus nephritis requires more innovative drugs to improve efficacy, reduce recurrence, delay or prevent the progression of end-stage renal failure, and improve the clinical outcome of patients.The release of belliumab as an indication for lupus nephritis also reveals the direction of future treatment.Professor Zeng Xiaofeng, director of rheumatology and Immunology Department of Peking Union Medical College Hospital, believes that lupus, as an autoimmune disease involving multiple systems throughout the body, will cause irreversible damage to the kidney and other important organs of the human body, and may even endanger life.Therefore, the goal of disease treatment is not only to achieve clinical remission, but also to reduce disease complications and drug side effects under the condition of controlling the disease, so as to reduce the cumulative damage of tissues and organs and improve the long-term survival rate and quality of life of patients.”The kidney is the organ most commonly affected by SLE, and if lupus nephritis is not well controlled it can lead to recurrent episodes and more severe damage to the kidney,” he said.Compared with traditional glucocorticoids and immunosuppressants, the most innovative value of bio-targeted agents lies in their ability to selectively inhibit self-reactive lymphocytes and reduce the use of other drugs and the occurrence of adverse reactions.With the widespread availability of precision targeted biologics such as belliuzumab, patients can be expected to delay the damage of systemic organs in and out of the kidney caused by long-term, high-dose hormones and immunosuppressants.”Collection and writing: Nandu reporter Zeng Wenqiong Intern: Tang Jing Yang